Preliminary Results of a Phase 1, Dose‑Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed / Refractory Lymphoid Malignancies

Katharine L. Lewis, Wojciech Jurczak, Gareth P. Gregory,Constantine S. Tam, Won Seog Kim,Eliza A. Hawkes, Franck Morschhauser, Sarit E. Assouline, Geoffrey Shouse, Petra Langerbeins, Monica Tani, Young Rok Do, Bruce D. Cheson, Catherine S. Diefenbach, Craig A. Portell, Jennifer Xavier, Muhtarjan Osman, Siminder K. Atwal, Wan‑Jen Hong, Clémentine Sarkozy